45 related articles for article (PubMed ID: 38627125)
1. Genetic Testing Utilization: Discrepancies Between Somatic and Germline Results in Patients With Cancer Reviewed at the UW Health Precision Medicine Molecular Tumor Board.
Horn IP; Zakas AL; Smith-Simmer KJ; Birkeland LE; Sundstrom R; Burkard ME; Weiss JM
JCO Precis Oncol; 2024 May; 8():e2300466. PubMed ID: 38810171
[TBL] [Abstract][Full Text] [Related]
2. Multiple Primary Cancers With Hematologic Malignancies and Germline Predisposition: A Case Series.
Yun J; Lee DS; Lee S; Yun H
Ann Lab Med; 2024 Sep; 44(5):446-449. PubMed ID: 38449380
[TBL] [Abstract][Full Text] [Related]
3. Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories.
Raymond VM; Gray SW; Roychowdhury S; Joffe S; Chinnaiyan AM; Parsons DW; Plon SE;
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26590952
[TBL] [Abstract][Full Text] [Related]
4. Ethical frameworks for obtaining informed consent in tumour profiling: an evidence-based case for Singapore.
Bylstra Y; Lysaght T; Thrivikraman J; Watson S; Tan P
Hum Genomics; 2017 Dec; 11(1):31. PubMed ID: 29221462
[TBL] [Abstract][Full Text] [Related]
5. Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.
Deans ZC; Costa JL; Cree I; Dequeker E; Edsjö A; Henderson S; Hummel M; Ligtenberg MJ; Loddo M; Machado JC; Marchetti A; Marquis K; Mason J; Normanno N; Rouleau E; Schuuring E; Snelson KM; Thunnissen E; Tops B; Williams G; van Krieken H; Hall JA;
Virchows Arch; 2017 Jan; 470(1):5-20. PubMed ID: 27678269
[TBL] [Abstract][Full Text] [Related]
6. The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?
Liu YL; Stadler ZK
J Natl Compr Canc Netw; 2021 Jul; 19(7):871-878. PubMed ID: 34340209
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet.
Ngeow J; Eng C
NPJ Genom Med; 2016; 1():15006. PubMed ID: 29263804
[TBL] [Abstract][Full Text] [Related]
8. Tumour predisposition and cancer syndromes as models to study gene-environment interactions.
Carbone M; Arron ST; Beutler B; Bononi A; Cavenee W; Cleaver JE; Croce CM; D'Andrea A; Foulkes WD; Gaudino G; Groden JL; Henske EP; Hickson ID; Hwang PM; Kolodner RD; Mak TW; Malkin D; Monnat RJ; Novelli F; Pass HI; Petrini JH; Schmidt LS; Yang H
Nat Rev Cancer; 2020 Sep; 20(9):533-549. PubMed ID: 32472073
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic yield and clinical impact of germline sequencing in children with CNS and extracranial solid tumors-a nationwide, prospective Swedish study.
Tesi B; Robinson KL; Abel F; Díaz de Ståhl T; Orrsjö S; Poluha A; Hellberg M; Wessman S; Samuelsson S; Frisk T; Vogt H; Henning K; Sabel M; Ek T; Pal N; Nyman P; Giraud G; Wille J; Pronk CJ; Norén-Nyström U; Borssén M; Fili M; Stålhammar G; Herold N; Tettamanti G; Maya-Gonzalez C; Arvidsson L; Rosén A; Ekholm K; Kuchinskaya E; Hallbeck AL; Nordling M; Palmebäck P; Kogner P; Smoler GK; Lähteenmäki P; Fransson S; Martinsson T; Shamik A; Mertens F; Rosenquist R; Wirta V; Tham E; Grillner P; Sandgren J; Ljungman G; Gisselsson D; Taylan F; Nordgren A
Lancet Reg Health Eur; 2024 Apr; 39():100881. PubMed ID: 38803632
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Only Sequencing: A Story Only Half Told.
Ceyhan-Birsoy O; Stadler ZK
JCO Precis Oncol; 2024 May; 8():e2400226. PubMed ID: 38810205
[TBL] [Abstract][Full Text] [Related]
11. Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer:
Subbiah V; Kurzrock R
J Clin Oncol; 2023 Jun; 41(17):3100-3103. PubMed ID: 36930859
[No Abstract] [Full Text] [Related]
12. Germline variants alter immune surveillance.
Waddell N; Addala V
Science; 2024 May; 384(6699):961-962. PubMed ID: 38815045
[TBL] [Abstract][Full Text] [Related]
13. Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort.
Winzeler B; Tufton N; S Lim E; Challis BG; Park SM; Izatt L; Carroll PV; Velusamy A; Hulse T; Whitelaw BC; Martin E; Rodger F; Maranian M; Clark GR; A Akker S; Maher ER; Casey RT
Clin Endocrinol (Oxf); 2022 Oct; 97(4):448-459. PubMed ID: 34870338
[TBL] [Abstract][Full Text] [Related]
14. Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels.
Akras Z; Bungo B; Leach BH; Marquard J; Ahluwalia M; Carraway H; Grivas P; Sohal DPS; Funchain P
JCO Precis Oncol; 2019 Dec; 3():1-11. PubMed ID: 35100683
[TBL] [Abstract][Full Text] [Related]
15. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
16. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
[TBL] [Abstract][Full Text] [Related]
17. Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.
Roggia C; Armeanu-Ebinger S; Gschwind A; Seibel-Kelemen O; Hertler S; Faust U; Liebmann A; Haack TB; Neumann M; Bonzheim I; Forschner A; Kopp HG; Herster F; Hartkopf A; Bitzer M; Malek NP; Brecht IB; Ruhm K; Möller Y; Löwenheim H; Ossowski S; Rieß OH; Schroeder C
Eur J Cancer; 2023 Jan; 179():48-55. PubMed ID: 36495689
[TBL] [Abstract][Full Text] [Related]
18. Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.
Al-Shinnag M; Cheong PL; Goodwin A; Trent R; Yu B
Pathology; 2024 Jun; 56(4):468-472. PubMed ID: 38627125
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
